The current trend of increasing infections by multidrug-resistant pathogens requires the discovery of novel antimicrobial agents with new target and selective toxicity towards pathogens. Menaquinone is a component of electron transport chains in a majority of anaerobic bacteria and Gram-positive bacteria. Due to its exclusivity in bacteria, menaquinone is thought to be a potential target for development of therapeutically effective antibacterial agents without side effects. In this review, we summarize inhibitors of menaquinone biosynthesis and antibiotics directly targeting menaquinone in bacteria.
No takes yet. Share an insight, caveat, or question.
Paudel et al. (2016) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: